Arthur A. Levin - 10 Jun 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Director
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
10 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 18:35:24 UTC
Previous filing
04 Jun 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEVIN ARTHUR A Director C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 12 Jun 2025 0001181556

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Award $0 +6,692 +52% $0.000000 19,650 10 Jun 2025 Direct F1
holding RNA Common Stock 131,372 10 Jun 2025 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Award $0 +10,034 $0.000000 10,034 10 Jun 2025 Common Stock 10,034 $33.62 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date.
F2 This option shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date.